SS 18 - Heme 2: Breaking through Resistance: Novel Approaches in NHL Radiation Therapy

Moderator(s)

• RB

  Richard Bakst, MD

  Mount Sinai School of Medicine
  NEW YORK, NY, United States
• 

  Michael LaRiviere, MD

  University of Pennsylvania
  Philadelphia, PA

Presentations:

• 10:45 AM – 10:55 AM ET

  Bridging Radiotherapy for Patients with Limited (<5 Disease Sites) Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma prior to CAR T-Cell Therapy
  

  Presenter: Omran Saifi, MD – Mayo Clinic Florida
• 10:55 AM – 11:05 AM ET

  Improvement in Radiomic Features Following Bridging Therapy is Prognostic for CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcome
  

  Presenter: Brandon Imber, MD, MS – Memorial Sloan Kettering Cancer Center
• 11:05 AM – 11:15 AM ET

  Multi-Institutional Update on Salvage Radiation Therapy in Relapsed/Refractory Large B Cell Lymphoma Patients in Post-CAR T Cell Therapy Failure
  

  Presenter: Chirayu Patel, MD, MD, MPH – Massachusetts General Hospital
• 11:15 AM – 11:25 AM ET

  Does CAR T-Cell Level during Post-CART DLBCL Progression Influence the Response to Salvage Radiotherapy and Patient Outcomes?
  

  Presenter: Jiaqi Fan, MD – University Cologne
• 11:25 AM – 11:35 AM ET

  Phase I Hypofractionation Trial of Relapsed/Refractory Lymphoma: Preliminary Results
  

  Presenter: Greeshma Rajeev-Kumar, MD – University of Chicago Medicine
• 11:35 AM – 11:45 AM ET

  Defining the Role of Radiotherapy for Indolent, Primary Cutaneous B-Cell Lymphoma - First Results from a Multicenter Registry by the International Lymphoma Radiation Oncology Group (ILROG)
  

  Presenter: Michael Oertel, MD – University Hospital of Muenster
• 11:45 AM – 11:55 AM ET

  Discussant
  

  Discussant: John Plastaras, MD, PhD – University of Pennsylvania